Lv3
380 积分 2023-10-17 加入
Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non–Small-Cell Lung Cancer Harboring ROS1 Rearrangement
18小时前
待确认
Taletrectinib in ROS1 + Non–Small Cell Lung Cancer: TRUST
19小时前
已完结
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1–2 trial
19小时前
已完结
Immunological alterations in the endothelial barrier: a new predictive and therapeutic paradigm for sepsis
1个月前
已完结
Single-Cell and Spatial Transcriptome Profiling Identifies the Transcription Factor BHLHE40 as a Driver of EMT in Metastatic Colorectal Cancer
2个月前
已完结
Quantifying cell divisions along evolutionary lineages in cancer
2个月前
已完结
Bone morphogenetic protein 9 is a candidate prognostic biomarker and host-directed therapy target for sepsis
3个月前
已完结
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
4个月前
已完结
Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)
7个月前
已完结
Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial
7个月前
已完结
皖公网安备34019202002308
